Table 2 from Repurposing Vandetanib plus Everolimus for the Treatment of &lt;i&gt;ACVR1&lt;/i&gt;-Mutant Diffuse Intrinsic Pontine Glioma

Diana Carvalho; Peter J. Richardson; Nagore G. Olaciregui; Reda Stankunaite; Cinzia Lavarino; Valeria Molinari; Elizabeth A. Corley; Daniel P. Smith; Ruth Ruddle; Adam Donovan; Ákos Pál; Florence I. Raynaud; Sara Temelso; Alan Mackay; John P. Overington; Anne M. Phelan; David N. Sheppard; Andrew L. MacKinnon; Bassel Zebian; Safa Al‐Sarraj; Ashirwad Merve; Jeremy Pryce; Jacques Grill; Michael Hubank; Ofelia Cruz; Andrés Morales La Madrid; Sabine Mueller; Ángel M. Carcaboso; Fernando Carceller; Chris Jones

doi:10.1158/2159-8290.30834226

Abstract

Summary of toxicities graded as per Common Terminology Criteria for Adverse Events version 4.03 related to vandetanib and/or mTOR inhibitors in three children with newly diagnosed ACVR1-mutant DIPG for a total of 9 cycles of vandetanib and 12 cycles of mTOR-inhibitor (11 cycles of everolimus and 1 cycle of sirolimus)

Related Publications

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Roger Stupp , Monika E. Hegi , Warren Mason +21 more

In 2004, a randomised phase III trial by the European Organisation for Research and Treatment of Cancer (EORTC) and National Cancer Institute of Canada Clinical Trials Group (NC...

2009 The Lancet Oncology 7605 citations

Publication Info

Year: 2025
Type: article
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Table 2 from Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Diana Carvalho, 
                                
                                    Peter J. Richardson, 
                                
                                    Nagore G. Olaciregui
                                
                                et al.
                            
                            (2025). 
                            Table 2 from Repurposing Vandetanib plus Everolimus for the Treatment of &lt;i&gt;ACVR1&lt;/i&gt;-Mutant Diffuse Intrinsic Pontine Glioma. 
                            
                            .
                            https://doi.org/10.1158/2159-8290.30834226

Identifiers

DOI: 10.1158/2159-8290.30834226